Quality Evaluation of Animal Experimental Studies on Prevention and Treatment of Atherosclerosis byTraditional Chinese Medicine Compound Formula：Literatures during 2017—2022

LI Ruoqi; ZHENG Danping; LI Yingying; TANG Danli; SUI Yu

doi:10.13288/j.11-2166/r.2023.09.008

您当前的位置：

首页 >

文章列表页 >

Quality Evaluation of Animal Experimental Studies on Prevention and Treatment of Atherosclerosis byTraditional Chinese Medicine Compound Formula：Literatures during 2017—2022

更新时间：2023-04-27

- Quality Evaluation of Animal Experimental Studies on Prevention and Treatment of Atherosclerosis byTraditional Chinese Medicine Compound Formula：Literatures during 2017—2022
- Journal of Traditional Chinese Medicine Vol. 64, Issue 9, Pages: 901-908(2023)
- 作者机构：
  
  1.中国中医科学院医学实验中心，北京市东城区东直门内南小街16号，100700
  2.中国中医科学院中医药信息研究所
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2023.09.008
  CLC：
- Received：01 August 2022，
  
  Revised：2022-11-26，
  
  Published：02 May 2023
- 稿件说明：
移动端阅览
李若琪,郑丹平,李盈盈等.2017—2022年发表的中药复方防治动脉粥样硬化动物实验文献的质量评价[J].中医杂志,2023,64(09):901-908.

LI Ruoqi, ZHENG Danping, LI Yingying, et al. Quality Evaluation of Animal Experimental Studies on Prevention and Treatment of Atherosclerosis byTraditional Chinese Medicine Compound Formula：Literatures during 2017—2022[J]. Journal of Traditional Chinese Medicine, 2023, 64(9): 901-908.
李若琪,郑丹平,李盈盈等.2017—2022年发表的中药复方防治动脉粥样硬化动物实验文献的质量评价[J].中医杂志,2023,64(09):901-908. DOI： 10.13288/j.11-2166/r.2023.09.008.

LI Ruoqi, ZHENG Danping, LI Yingying, et al. Quality Evaluation of Animal Experimental Studies on Prevention and Treatment of Atherosclerosis byTraditional Chinese Medicine Compound Formula：Literatures during 2017—2022[J]. Journal of Traditional Chinese Medicine, 2023, 64(9): 901-908. DOI： 10.13288/j.11-2166/r.2023.09.008.

摘要

目的

通过评价中药复方防治动脉粥样硬化（AS）动物实验文献的方法学质量及报告质量，分析实验过程中的偏倚风险及研究报告的不足，寻求提高中药复方防治AS动物实验研究质量的方法。

方法

计算机检索中国知网（CNKI）、万方数据知识服务平台（WF）、维普中文期刊服务平台（VIP）、中国生物医学文献数据库（SinoMed）、PubMed、Web of science、Cochrane library和Embase数据库，收集2017年1月1日至2022年9月20日发表的中药复方防治AS动物实验文献，基于SYRCLE偏倚风险评估工具和ARRIVE 指南对纳入的文献进行评分并计算各条目“低风险”符合率。

结果

初步筛选出7921篇文献，最终纳入符合要求的文献343篇，其中中文文献301篇，英文文献42篇。SYRCLE工具评分为（13.26±1.26）分，“低风险”符合率为35.74%。ARRIVE指南必备条目评分为（24.39±1.65）分，“低风险”符合率为42.22%；推荐条目评分为（9.41±2.34）分，“低风险”符合率为20.10%。在SYRCLE工具评价中，245项（71.43%）研究未提供详细序列分配方法，所有研究均未在实施偏倚以及测量偏倚中报告有效的干预措施，仅有5项（1.46%）研究对基线特征进行了描述，2项（0.58%）研究在结果评估中报告了盲法的实施。在ARRIVE指南中，所有研究均未报告样本量确定方法、指定主要结局指标及注册计划书，仅有49项（14.29%）研究说明了实验分析中未包括的动物，54项（15.74%）研究提供了统计方法的详细信息，33项（9.62%）研究提供了实验动物的进一步信息。

结论

2017—2022年发表的中药复方防治AS动物实验文献方法学质量及报告质量存在较多问题，尤其是在实验过程中随机盲法的实施、实验数据报告的完整性方面存在较多缺陷，建议参照评价工具对研究进行设计和报告，从而提高实验研究的可信性与再现性。

Abstract

Objective

To explore the methods that can improve the quality of animal experiments on the prevention and treatment of atherosclerosis by traditional Chinese medicine （TCM） compound formula， by evaluating the methodological quality and reporting quality， and by analyzing the risk of bias in the experimental process and the inadequacy reporting of the researches.

Methods

CNKI，WanFang，VIP，SinoMed，PubMed，Web of science， Cochrane library and Embase databases were searched to collect animal experimental literature on the prevention and treatment of atherosclerosis by TCM compounds published between January 1st， 2017 and September 20th， 2022. The included literature was scored based on the SYRCLE bias risk assessment tool and ARRIVE 2019 guidelines， and the coincidence rate of “low risk” for each item was calculated.

Results

A total of 343 studies out of the initially screened 7921 studies were included， involving 301 in Chinese and 42 in English. The score of SYRCLE tool was 13.26±1.26，and the “low-risk” coincidence rate was 35.74%. The score of the ARRIVE guideline wass 24.39±1.65，and the “low-risk” coincidence rate was 42.22% of the essential items， while those were 9.41±2.34 and 20.10% of the recommended items. According to the SYRCLE's tool，245 studies （71.43%） did not provide details for sequence allocation reported no effective interventions in terms of selection bias，implementation bias，and measurement bias. Only five studies （1.46%） described baseline characteristics，and two studies （0.58%） reported the implementation of blinding in the outcome evaluation. None of the studies reported method of sample size determination，designation of primary outcome measure，and registration protocol in the ARRIVE guidelines. Only 49 studies （14.29%） identified animals not included in the analysis，and 54 studies （15.74%） provided details of the statistical method. Additional information on experimental animals was provided in 33 studies （9.62%）.

Conclusion

There are many problems in the methodological quality and reporting quality of animal experiments on the prevention and treatment of atherosclerosis by TCM compound formulas in literatures published during 2017—2022，especially in the implementation of the randomization and blinding during the experiments，and the adequate reporting of the experimental data report completeness.Therefore， it is recommended to design and report a study with reference to the evaluation tools， so as to improve the credibility and reproducibility of experimental studies.

关键词

Keywords

references

MAGUIRE EM ， PEARCE SWA ， XIAO Q . Foam cell formation：A new target for fighting atherosclerosis and cardiovascular disease ［J］. Vascul Pharmacol ， 2019 ， 112 （ 1 ）： 54 - 71 .

吴晓娟，林小娟，佟晓永 . 抗动脉粥样硬化药物的研究进展［J］. 生命科学仪器， 2018 ， 16 （ 6 ）： 16 - 24 .

LU L ， QIN Y ， ZHANG X ， et al . Shexiang Baoxin Pill alleviates the atherosclerotic lesions in mice via improving inflammation response and inhibiting lipid accumulation in the arterial wall ［J］. Mediators Inflamm ， 2019 ， 11 （ 7 ）： 13 - 26 .

陈羽斐，胡亮，张红旗，等 . 麝香保心丸对ApoE -/- 小鼠心肌梗死后动脉粥样硬化进程和循环单核细胞亚群的影响［J］. 中国中西医结合杂志， 2020 ， 40 （ 12 ）： 1478 - 1483 .

ZHANG Y ， GU Y ， CHEN Y ， et al . Dingxin Recipe Ⅳ attenuates atherosclerosis by regulating lipid metabolism through LXR-α/SREBP1 pathway and modulating the gut microbiota in ApoE -/- mice fed with HFD ［J］. J Ethnopharmacol ， 2021 ， 266 （ 10 ）： 113436 .

YANG R ， YIN D ， YANG D ， et al . Xinnaokang improves cecal microbiota and lipid metabolism to target atherosclerosis ［J］. Lett Appl Microbiol ， 2021 ， 73 （ 6 ）： 779 - 792 .

HOOIJMANS CR ， ROVERS MM ， DE VRIES RB ， et al . SYRCLE's risk of bias tool for animal studies ［J］. BMC Med Res Methodol ， 2014 ， 14 （ 43 ）： 1 - 9 .

KRAUTH D ， WOODRUFF TJ ， BERO L ， et al . Instruments for assessing risk of bias and other methodological criteria of published animal studies：a systematic review ［J］. Environ Health Perspect ， 2013 ， 121 （ 9 ）： 985 - 992 .

陈匡阳，马彬，王亚楠，等 . SYRCLE动物实验偏倚风险评估工具简介［J］. 中国循证医学杂志， 2014 ， 14 （ 10 ）： 1281 - 1285 .

HOOIJMANS CR ， RITSKES-HOITINGA M . Progress in using systematic reviews of animal studies to improve translational research ［J］. PLoS Med ， 2013 ， 10 （ 7 ）： e1001482 .

PERCIE DU SERT N ， AHLUWALIA A ， ALAM S ， et al . Reporting animal research：Explanation and elaboration for the ARRIVE guidelines 2.0 ［J］. PLoS Biol ， 2020 ， 18 （ 7 ）： e3000411 .

PERCIE DU SERT N ， HURST V ， AHLUWALIA A ， et al . The ARRIVE guidelines 2.0：Updated guidelines for reporting animal research ［J］. PLOS Biol ， 2020 ， 18 （ 7 ）： e3000410 .

ZHOU JM ， WANG HM ， LV YZ ， et al . Anti-atherosclerotic effect of Longxuetongluo Capsule in high cholesterol diet induced atherosclerosis model rats ［J］. Biomed Pharmacother ， 2018 ， 97 （ 1 ）： 793 - 801 .

MA J ， QIAO L ， MENG L ， et al . Tongxinluo may stabilize atherosclerotic plaque via multiple mechanisms scanning by genechip ［J］. Biomed Pharmacother ， 2019 ， 113 （ 5 ）： 108767 .

WANG A ， GUAN B ， SHAO C ， et al . Qing-Xin-Jie-Yu Granule alleviates atherosclerosis by reshaping gut microbiota and metabolic homeostasis of ApoE -/- mice ［J］. Phytomedicine ， 2022 ， 103 （ 8 ）： 154220 .

LIU B ， SONG Z ， YU J ， et al . The atherosclerosis-ameliorating effects and molecular mechanisms of Bu-YangHuanWu decoction ［J］. Biomed Pharmacother ， 2020 ， 123 （ 3 ）： 109664 .

盛松，徐凤芹，张艳虹 . 芎芍胶囊对动脉粥样硬化模型兔血脂和超敏C反应蛋白的影响［J］. 中西医结合心脑血管病杂志， 2019 ， 17 （ 17 ）： 2595 - 2598 .

陈宁，贾连群，宋囡，等 . 化瘀祛痰方对动脉粥样硬化家兔肝脏脂质沉积的影响［J］. 中医杂志， 2019 ， 60 （ 20 ）： 1755 - 1759 .

关乐 . 益脉颗粒抗动脉粥样硬化的疗效机制研究［D］. 沈阳：辽宁中医药大学， 2019 .

陈菁，于学玲，史志祥 . 中外科技期刊语体风格对比研究：以生物医药类期刊为例［J］. 科技与出版， 2017 ， 35 （ 1 ）： 91 - 94 .

Quality Evaluation of Animal Experimental Studies on Prevention and Treatment of Atherosclerosis by Traditional Chinese Medicine Compound Formula：Literatures during 2017 — 2022

LI Ruoqi 1 ， ZHENG Danping 2 ， LI Yingying 1 ， TANG Danli 1 ， SUI Yu 1

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Treating Vulnerable Atherosclerotic Plaque from the Perspective of "Abscess and Ulcer within the Vessels"

Effect of Jianpi Huazhuo Tiaozhi Granule（健脾化浊调脂颗粒）on Perivascular Adipose Tissue Browning and PI3K/AKT Pathway in the Aorta of Atherosclerosis Model Mice

Correlation Between Traditional Chinese Medicine Syndromes and Rheumatoid Arthritis with Atherosclerosis：A Multicenter Cross-Sectional Study

Time Sequential Differentiation and Treatment of Atherosclerosis Under the Guidance of the Theory of "Accumulation in Pulse"：Taking Coronary Heart Disease as An Example

Stage-Based Intervention in Atherosclerosis Using the "Attacking，Supplementing，Dispersing，Dissipating" Method Based on the Accumulation Syndrome Theory

Related Author

WANG Yajie

WU Min

ZHANG Zihao

WANG Zeping

LIU Longtao

WANG Zhuhua

WANG Yanfang

ZHONG Mingshu

Related Institution

Guang 'anmen Hospital，China Academy of Chinese Medical Sciences

Xiyuan Hospital，China Academy of Chinese Medical Sciences

Jiangxi University of Traditional Chinese Medicine

Ruijin Hospital of Traditional Chinese Medicine

Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰